269 related articles for article (PubMed ID: 11020562)
1. Rectal function following prostate brachytherapy.
Merrick GS; Butler WM; Dorsey AT; Galbreath RW; Blatt H; Lief JH
Int J Radiat Oncol Biol Phys; 2000 Oct; 48(3):667-74. PubMed ID: 11020562
[TBL] [Abstract][Full Text] [Related]
2. Late rectal function after prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Hines AL; Allen Z
Int J Radiat Oncol Biol Phys; 2003 Sep; 57(1):42-8. PubMed ID: 12909214
[TBL] [Abstract][Full Text] [Related]
3. Erectile function after permanent prostate brachytherapy.
Merrick GS; Butler WM; Galbreath RW; Stipetich RL; Abel LJ; Lief JH
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(4):893-902. PubMed ID: 11958881
[TBL] [Abstract][Full Text] [Related]
4. Rectal function following brachytherapy with or without supplemental external beam radiation: results of two prospective randomized trials.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Kurko B; Cleavinger S
Brachytherapy; 2003; 2(3):147-57. PubMed ID: 15062137
[TBL] [Abstract][Full Text] [Related]
5. Long-term urinary quality of life after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH
Int J Radiat Oncol Biol Phys; 2003 Jun; 56(2):454-61. PubMed ID: 12738320
[TBL] [Abstract][Full Text] [Related]
6. Influence of hormonal therapy on late rectal function after permanent prostate brachytherapy with or without supplemental external beam radiotherapy.
Merrick GS; Butler WM; Wallner KE; Murray BC; Allen Z; Galbreath RW
Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):68-74. PubMed ID: 14697422
[TBL] [Abstract][Full Text] [Related]
7. Long-term rectal function after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen ZA; Gutman S; Lief J
Cancer J; 2007; 13(2):95-104. PubMed ID: 17476137
[TBL] [Abstract][Full Text] [Related]
8. Patient-reported long-term rectal function after permanent interstitial brachytherapy for clinically localized prostate cancer.
Orio PF; Merrick GS; Galbreath RW; Butler WM; Lief J; Wallner KE
Brachytherapy; 2012; 11(5):341-7. PubMed ID: 22561216
[TBL] [Abstract][Full Text] [Related]
9. Temporal resolution of urinary morbidity following prostate brachytherapy.
Merrick GS; Butler WM; Lief JH; Dorsey AT
Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):121-8. PubMed ID: 10758313
[TBL] [Abstract][Full Text] [Related]
10. Morbidity effect of the time gap between supplemental beam radiation and Pd-103 prostate brachytherapy.
Corriveau J; Wallner K; Merrick G; True L; Cavanagh W; Sutlief S; Butler W
Brachytherapy; 2003; 2(2):108-13. PubMed ID: 15062149
[TBL] [Abstract][Full Text] [Related]
11. Effect of prostate size and isotope selection on dosimetric quality following permanent seed implantation.
Merrick GS; Butler WM; Dorsey AT; Lief JH
Tech Urol; 2001 Sep; 7(3):233-40. PubMed ID: 11575521
[TBL] [Abstract][Full Text] [Related]
12. Dysuria after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Murray B; Zeroski D; Lief JH
Int J Radiat Oncol Biol Phys; 2003 Mar; 55(4):979-85. PubMed ID: 12605976
[TBL] [Abstract][Full Text] [Related]
13. The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy.
Niehaus A; Merrick GS; Butler WM; Wallner KE; Allen ZA; Galbreath RW; Adamovich E
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):136-43. PubMed ID: 16198062
[TBL] [Abstract][Full Text] [Related]
14. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
15. The dosimetry of prostate brachytherapy-induced urethral strictures.
Merrick GS; Butler WM; Tollenaar BG; Galbreath RW; Lief JH
Int J Radiat Oncol Biol Phys; 2002 Feb; 52(2):461-8. PubMed ID: 11872293
[TBL] [Abstract][Full Text] [Related]
16. Erectile function after prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Anderson RL; Kurko BS; Lief JH; Allen ZA
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):437-47. PubMed ID: 15890585
[TBL] [Abstract][Full Text] [Related]
17. I-125 versus Pd-103 for low-risk prostate cancer: long-term morbidity outcomes from a prospective randomized multicenter controlled trial.
Herstein A; Wallner K; Merrick G; Mitsuyama H; Armstrong J; True L; Cavanagh W; Butler W
Cancer J; 2005; 11(5):385-9. PubMed ID: 16259869
[TBL] [Abstract][Full Text] [Related]
18. Placement of an absorbable rectal hydrogel spacer in patients undergoing low-dose-rate brachytherapy with palladium-103.
Taggar AS; Charas T; Cohen GN; Boonyawan K; Kollmeier M; McBride S; Mathur N; Damato AL; Zelefsky MJ
Brachytherapy; 2018; 17(2):251-258. PubMed ID: 29241706
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Lief JH; Galbreath RW
Urology; 2002 Oct; 60(4):650-5. PubMed ID: 12385927
[TBL] [Abstract][Full Text] [Related]
20. Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer.
Merrick GS; Butler WM; Galbreath RW; Lief JH
Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):41-8. PubMed ID: 11516849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
